Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/AIA.0000000000000208 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mitral transcatheter-edge-to-edge-repair after failed Alfieri stitch: an effective alternative to re-do surgery.
J Invasive Cardiol
January 2025
Division of Cardiology, Mount Sinai Heart Fuster Hospital, Icahn School of Medicine at Mount Sinai, New York, New York. Email:
Transcatheter edge-to-edge repair of severe atrioventricular valve regurgitation in unrepaired functionally univentricular heart with dextroversion.
J Invasive Cardiol
January 2025
Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Cardiology Division, Department of Medicine, Queen Mary Hospital, Hong Kong SAR, China; Cardiac Medical Unit, Grantham Hospital, Hong Kong SAR, China.
Transcatheter Atrioventricular Valve Repair and Replacement Technologies in Pediatric and Adult Congenital Heart Disease: A Paradigm for Improving Access.
J Soc Cardiovasc Angiogr Interv
December 2024
Gore & Associates, Newark, Delaware.
Strategic Management of Valve Infolding in Evolut TAVR Procedures: Enhancing Outcomes and Ensuring Patient Safety.
J Soc Cardiovasc Angiogr Interv
December 2024
Cardiovascular Institute, Detroit Medical Center, DMC Heart Hospital, Detroit, Michigan.
Transcatheter aortic valve repair (TAVR) presents a minimally invasive alternative to traditional surgical valve replacement, albeit not without its own set of complications. A rare complication is the infolding of the self-expanding valve, which can precipitate cardiac arrest. The estimated incidence rate of this complication stands at 1.
View Article and Find Full Text PDFManagement of Acute Coronary Syndrome in Patients With Transcatheter Aortic Valve Replacement: A Review.
Catheter Cardiovasc Interv
January 2025
Department of Medicine, Michael E DeBakey Veteran's Affairs Medical Center, Houston, Texas, USA.
Transcatheter aortic valve replacement (TAVR) has become a viable treatment option for patients with severe aortic stenosis among all risk subsets. As TAVR use becomes more prevalent and patients live longer with their transcatheter valve, an increasing number of these patients can be expected to present with ACS. Overall, there is a paucity of high-quality data detailing incidence, pathophysiology, and management of ACS in this subset.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!